Deuterium-enriched prasugrel
The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1. A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 5 and R 7 -R 20 are H, and R 6 is D.
2. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
3. A method for treating percutaneous coronary intervention comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
4. A compound of claim 1 , wherein the compound is represented by
or a pharmaceutically acceptable salt form thereof, wherein R 1 -R 5 and R 7 -R 20 are H and R 6 is D.
5. A compound of claim 1 , wherein the compound is represented by
or a pharmaceutically acceptable salt form thereof, wherein R 1 -R 5 and R 7 -R 20 are H, and R 6 is D.
6. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1 .
7. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 4 .
8. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 5 .
9. A method for treating percutaneous coronary intervention comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 4 to treat said percutaneous coronary intervention.
10. A method for treating percutaneous coronary intervention comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 5 to treat said percutaneous coronary intervention.